Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01455064 · ClinicalTrials.gov registry record

Navigator II Continuous Glucose Monitor Home Use Study

A clinical trial of Diabetes, sponsored by Abbott Diabetes Care.

Completed
Registry status
31
Enrollment target
2
Study locations

NCT01455064 is a study of Diabetes that has completed, run by Abbott Diabetes Care. The registered enrollment target is 31 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01455064, a study of Diabetes, has completed, sponsored by Abbott Diabetes Care.

COMPLETED
Registry status
31 participants
Enrollment target
2
Study locations

Study Summary

This research study will test a new investigational continuous glucose monitoring system (System). The purpose of this study is to find out about the performance of the System in a home use environment over a 15 day period, in people with diabetes.

Conditions Studied

Interventions

  • DEVICE FreeStyle Navigator II Continuous Glucose Monitoring System

Study Locations (2)

Georgia

  • Atlanta Diabetes Associates - Atlanta

New Mexico

  • Southwest Clinical Research Center - Santa Fe

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2011-10
Est. Completion 2012-01

Sponsor

Abbott Diabetes Care

26 total trials

What the Registry Record Tells You About NCT01455064

The ClinicalTrials.gov registry entry for NCT01455064 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Abbott Diabetes Care, which has 26 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which FreeStyle Navigator II Continuous Glucose Monitoring System is the first listed.

NCT01455064 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, New Mexico.

Frequently Asked Questions

What is clinical trial NCT01455064 about?

NCT01455064 is a clinical study titled "Navigator II Continuous Glucose Monitor Home Use Study". This research study will test a new investigational continuous glucose monitoring system (System). The purpose of this study is to find out about the performance of the System in a home use environment over a 15 day period, in people with diabetes.

What is the current status of trial NCT01455064?

This trial is currently completed. The enrollment target is 31 participants. The study started on 2011-10. Estimated completion is 2012-01.

What conditions does trial NCT01455064 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT01455064?

The interventions under investigation include: FreeStyle Navigator II Continuous Glucose Monitoring System (DEVICE).

Who is sponsoring clinical trial NCT01455064?

This trial is sponsored by Abbott Diabetes Care, which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01455064 being conducted?

This trial has 2 study locations across Georgia, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.